PARP inhibitors (PARPi) are current treatment options for patients with ovarian, breast, pancreatic, and prostate cancer harboring mutations in BRCA1 or BRCA2 (BRCAm) but they have also been approved in broader patient populations in ovarian and prostate cancer (5–7). Here, BRCA1 is linked to prostate cancer.